Sanofi (SNY) Operating Income (2009 - 2026)
Sanofi (SNY) posted Operating Income of $16.3 billion for Q2 2026, up 13.96% sequentially from $14.3 billion in Q1 2026, and up 20.28% YoY from $13.5 billion in Q2 2025.
Sanofi (SNY) Operating Income (2009 - 2026) Analysis & Trends
Sanofi has reported Operating Income for 18 years, with the latest figure at $16.3 billion in Q2 2026.
- Quarterly Operating Income rose 20.28% year-over-year to $16.3 billion in Q2 2026, while the trailing twelve-month figure through Jun 2026 was $86.5 billion (up 35.23% YoY) and the FY2025 annual result came in at $7.4 billion, down 4.71% from the prior year.
- Operating Income climbed to $16.3 billion in Q2 2026 per SNY's latest filing, from $14.3 billion in the prior quarter.
- Over five years, Operating Income peaked at $47.8 billion in Q4 2023 and troughed at $11.4 billion in Q1 2024.
- A 5-year average of $18.9 billion and a median of $13.7 billion in 2022 frame the typical range for Operating Income.
- The sharpest annual moves came in 2024 and 2025: Operating Income tumbled 50.96% in 2024, then surged 199.59% in 2025.
- Over 5 years, Operating Income stood at $40.1 billion in 2022, then rose by 19.08% to $47.8 billion in 2023, then sank by 50.96% to $23.4 billion in 2024, then sank by 48.49% to $12.1 billion in 2025, then jumped by 34.57% to $16.3 billion in 2026.
- According to Business Quant data, Operating Income over the past three periods registered $16.3 billion, $14.3 billion, and $12.1 billion for Q2 2026, Q1 2026, and Q4 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Op. Inc (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 653.32 Bn | 632.56 Bn | 17.26 Bn | 7.14 Bn |
| 2 | AbbVie | 470.11 Bn | 463.54 Bn | 12.70 Bn | 6.43 Bn |
| 3 | Merck | 376.14 Bn | 369.00 Bn | 12.21 Bn | -584.00 Mn |
| 4 | Novartis Ag | 303.26 Bn | 295.57 Bn | 11.24 Bn | 4.75 Bn |
| 5 | Astrazeneca | 257.39 Bn | 252.49 Bn | 12.86 Bn | 3.16 Bn |
| 6 | Amgen | 236.59 Bn | 222.60 Bn | 7.24 Bn | 3.51 Bn |
| 7 | Gilead Sciences | 181.91 Bn | 178.73 Bn | 6.22 Bn | -10.39 Bn |
| 8 | Pfizer | 159.26 Bn | 147.57 Bn | 10.94 Bn | 4.27 Bn |
| 9 | Gsk | 106.16 Bn | 101.99 Bn | 8.24 Bn | 645.35 Mn |
| 10 | Sanofi | 55.11 Bn | 47.73 Bn | 10.79 Bn | 16.77 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 16.25 Bn |
| Mar 31, 2026 | 14.26 Bn |
| Dec 31, 2025 | 12.08 Bn |
| Sep 30, 2025 | 43.92 Bn |
| Jun 30, 2025 | 13.51 Bn |
| Mar 31, 2025 | 12.36 Bn |
| Dec 31, 2024 | 23.44 Bn |
| Sep 30, 2024 | 14.66 Bn |
| Jun 30, 2024 | 11.87 Bn |
| Mar 31, 2024 | 11.45 Bn |
| Dec 31, 2023 | 47.80 Bn |
| Sep 30, 2023 | 14.26 Bn |
| Jun 30, 2023 | 12.65 Bn |
| Mar 31, 2023 | 12.83 Bn |
| Dec 31, 2022 | 40.14 Bn |
| Sep 30, 2022 | 13.80 Bn |
| Jun 30, 2022 | 12.51 Bn |
| Mar 31, 2022 | 12.39 Bn |
| Dec 31, 2021 | 35.33 Bn |
| Sep 30, 2021 | 13.33 Bn |